Veradermics (MANE) said Monday it has completed enrollment in its second phase 3 registration-directed trial of VDPHL01 for male pattern hair loss, bringing enrollment to completion across both phase 3 studies in men totaling more than 1,000 participants.

The phase 3 '304' study is a randomized, placebo-controlled trial evaluating once- and twice-daily dosing over 52 weeks in 536 men with mild-to-moderate hair loss, with co-primary endpoints of changes in non-vellus hair count and patient-reported hair coverage at 24 weeks, the company said, adding that topline data is expected in H2.

The completion of the second Phase 3 trial's enrollment follows the closing of enrollment in Veradermics' phase 2/3 male trial, with topline data expected in H1, the company said.

Veradermics said it is also enrolling patients in a phase 2/3 trial of VDPHL01 in females with pattern hair loss.